C ases of acute hepatitis related to intravenous methyl/prednisolone (IVMP) therapy have previously been described in patients treated for multiple sclerosis (MS) relapses, [1] [2] [3] [4] [5] in a patient with central nervous system vasculitis and in patients with Graves ophtalmopathy. Severe steatohepatitis and liver failure were fatal in another 3 patients treated with prednisolone for lupus erythematosus systemicus, dermatomyositis, and Graves ophtalmopathy (reviewed in Gutkowski et al 2 ) .
We report 4 cases of liver injury following IVMP therapy (1 g for 5 d) in patients treated for MS relapses for the first time. All patients had normal blood chemistry before treatment, they denied alcohol intake, and no concomitant medications were taken except for lisinopril in case 1. Diagnostic work-up was normal in all patients, except for case 3 (vide infra), and entailed serological tests for HAV, HBV, HCV, EBV, CMV AQ2 and syphilis, dosage of antinuclear (ANA) and antismooth muscle antibodies (ASMA), antimitochondrial antibodies, liver-kidney microsomal antibodies, iron, serum ferritine, blood lipid profile, serum ceruloplasmin, and liver ultrasound. Liver biopsy was performed in cases 3 and 4 and showed, in both the cases, inflammatory infiltrates, focal piecemeal necrosis, periportal fibrosis, and numerous ceroid-laden macrophages.
DISCUSSION
Drug-induced liver injury is mediated by either an intrinsic, dose-dependent, and predictable mechanism, or by an idiosyncratic, dose-independent, and unpredictable mechanism. The clinical expression of drug-induced disease is highly variable, including minimal and asymptomatic liver enzyme elevations, acute or chronic hepatitis, cholestatic liver disease, and acute liver insufficiency. Criteria favorable to a diagnosis include exclusion of alternative causes of liver damage, demonstration of clinical and serological improvement after dechallenge, and the reappearance of alterations after rechallenge. 6 The conjunction of clinical, laboratory, and histologic data; the exclusion of other causes of hepatic profile changes; and the rechallenge in 1 patient, suggest that hepatitis in our patients was probably related to an idiosyncratic reaction to IVMP treatment except maybe in patient 3. Patient 3 had a positivity for ANA and ASMA and we cannot rule out an autoimmune hepatitis (AIH), although the liver biopsy did not suggest this diagnosis, as there have been reports of AIH developing after methylprednisolone (MP) treatment, 7 the hypothesis being that of a rebound phenomenon after discontinuation of immunosuppressive regimens.
High-dose MP is the only recommended first-line treatment of MS exacerbations. Plasma exchange may be considered for patients who have not responded to MP, although only about one third of patients are likely to respond, and there is insufficient data to support the use of intravenous immunoglobulins as monotherapy for MS relapses. 8, 9 As a consequence, treatment of MS relapses becomes challenging if IV steroids are not a safe choice. Further studies on current second-line and third-line treatments such as plasma exchange and intravenous immunoglobulins and on possible alternative treatment regimens are needed.
Glucocorticoid-induced liver toxicity is probably more frequent than it may appear and it is a known entity among hepatologists. However, neurologists and other specialists who are faced with exacerbations of autoimmune diseases may not be aware of the risk of high-dose corticosteroid therapy. Considering the widespread use of short-term high-dose regimens of corticosteroids, it is important to highlight the importance of this possible, potentially lethal, adverse reaction
